Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.90 -0.05 (-5.54%)
As of: Oct 1, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Return on Equity [ROE] (2011 - 2026)

Updated

Lineage Cell Therapeutics (LCTX) posted Return on Equity [ROE] of -56.52% for Q2 2026, up 8.82 percentage points from -65.33% a year earlier and up 75.14 percentage points from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Return on Equity [ROE] (2011 - 2026) Analysis & Trends

For FY2025, Lineage Cell Therapeutics' Return on Equity [ROE] came in at -104.26%, down 77.53 percentage points from FY2024.

  • Annual Return on Equity [ROE] shows a five-year change of -84.21 percentage points (FY2020 to FY2025).
  • In prior years, Lineage Cell Therapeutics' Return on Equity [ROE] was -26.73% in FY2024 (+5.34 pp), -32.07% in FY2023 (+0.30 pp), -32.37% in FY2022 (+14.15 pp) and -46.52% in FY2021 (-26.47 pp).
  • The Q2 2026 figure stands as the highest quarterly Return on Equity [ROE] since Q1 2025.
  • On a year-over-year basis, Return on Equity [ROE] increased in four of the last eight quarters, with an average year-over-year change of -54.52 percentage points.
  • The strongest year-over-year quarter for Return on Equity [ROE] in the past five years was Q2 2023, with a gain of 29.57 percentage points; the weakest was Q3 2025, with a drop of 164.80 percentage points.
  • According to Business Quant data, Return on Equity [ROE] for the three prior quarters was -131.65% (Q1 2026), -190.32% (Q4 2025) and -195.25% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Lineage Cell Therapeutics 240.26 Mn 38.67 Mn - -56.52%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -56.52%
Mar 31, 2026 -131.65%
Dec 31, 2025 -190.32%
Sep 30, 2025 -195.25%
Jun 30, 2025 -65.33%
Mar 31, 2025 -20.91%
Dec 31, 2024 -26.21%
Sep 30, 2024 -30.45%
Jun 30, 2024 -35.11%
Mar 31, 2024 -35.53%
Dec 31, 2023 -33.38%
Sep 30, 2023 -33.54%
Jun 30, 2023 -31.49%
Mar 31, 2023 -33.58%
Dec 31, 2022 -35.26%
Sep 30, 2022 -61.84%
Jun 30, 2022 -61.06%
Mar 31, 2022 -55.55%
Dec 31, 2021 -41.11%
Sep 30, 2021 -9.90%
API Access

Lineage Cell Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=LCTX&period=max&api_key=YOUR_API_KEY